Kristen Ciombor
Last active: 9/11/2013

Profile

Education/Training:

Sept 1997-June 2001       A.B. cum laude, Biochemical Sciences, Harvard University, Cambridge, Massachusetts

Aug 2001-May 2005         M.D., University of Miami Miller School of Medicine, Miami, Florida

June 2005-June 2008       Intern and Resident, Department of Internal Medicine, University of Miami/Jackson   Memorial Hospital/Miami Veterans Administration, Miami, Florida

July 2008-June 2009        Chief Resident, Department of Internal Medicine, University of Miami/Jackson Memorial Hospital/Miami Veterans Administration, Miami, Florida

July 2009-June 2013         Fellow, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee

July 2011-May 2013          M.S., Clinical Investigation, Vanderbilt University, Nashville, Tennessee

Licensure and Certification:

2008-2010                            Florida Board of Medical Examiners License No. ME102203

2013-present                        Ohio Board of Medical Examiners License No. 35.121390

2008-2018                            American Board of Internal Medicine Certification in Internal Medicine

2012-2022                            American Board of Internal Medicine Certification in Medical Oncology

2012-2022                            American Board of Internal Medicine Certification in Hematology

Academic Appointments:

8/1/2013-present                 Assistant Professor, Ohio State University, Division of Medical Oncology

Professional Organizations:

2007-2009                            American College of Physicians, Member

2009-present                        American Society of Clinical Oncology, Member

2010-2011                            American Society of Hematology, Member

2010-present                        American Association for Cancer Research, Member

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Current therapy and future directions in biliary tract malignancies. Ciombor KK, Goff LW (2013) Curr Treat Options Oncol 14(3): 337-49
    › Primary publication · 23686724 (PubMed) · PMC3769474 (PubMed Central)
  2. Aflibercept. Ciombor KK, Berlin J, Chan E (2013) Clin Cancer Res 19(8): 1920-5
    › Primary publication · 23444216 (PubMed) · PMC3710732 (PubMed Central)
  3. Advances in the management of biliary tract cancers. Ciombor KK, Goff LW (2013) Clin Adv Hematol Oncol 11(1): 28-34
    › Primary publication · 23416860 (PubMed) · PMC3713630 (PubMed Central)
  4. Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis. Gehrie E, Neff AT, Ciombor KK, Harris N, Seegmiller AC, Young PP (2012) Transfusion 52(1): 4-5
    › Primary publication · 22032241 (PubMed)
  5. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM (2012) Am J Clin Oncol 35(5): 446-50
    › Primary publication · 21552097 (PubMed)
  6. Management of small cell lung cancer. Ciombor KK, Rocha Lima CM (2006) Curr Treat Options Oncol 7(1): 59-68
    › Primary publication · 16343369 (PubMed)
  7. Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation. Martin KA, Schalm SS, Romanelli A, Keon KL, Blenis J (2001) J Biol Chem 276(11): 7892-8
    › Primary publication · 11108720 (PubMed)
  8. Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. Martin KA, Schalm SS, Richardson C, Romanelli A, Keon KL, Blenis J (2001) J Biol Chem 276(11): 7884-91
    › Primary publication · 11108711 (PubMed)